(Q37824712)

23 August 2017

1 reference

title

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes (English)

1 reference

23 August 2017

1 reference

acute myeloid leukemia

0 references

author

Thomas Prebet

series ordinal

1

0 references

author name string

Norbert Vey

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

31 December 2010

1 reference

Expert Opinion on Investigational Drugs

23 August 2017

published in

1 reference

23 August 2017

volume

20

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

287-295

1 reference

How I treat patients with myelodysplastic syndromes

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Acute myeloid leukemia and myelodysplastic syndromes in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Histone deacetylase inhibitors: biology and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Quantitative DNA methylation predicts survival in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Valproic acid for the treatment of myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Translating the histone code into leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Epigenetic mechanisms in AML - a target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

A phase 2 study of vorinostat in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542750

10.1517/13543784.2011.542750

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference